U.S. markets close in 5 hours 4 minutes
  • S&P 500

    -1.92 (-0.05%)
  • Dow 30

    +75.08 (+0.24%)
  • Nasdaq

    -127.62 (-1.00%)
  • Russell 2000

    -32.26 (-1.50%)
  • Crude Oil

    +1.80 (+2.82%)
  • Gold

    -4.10 (-0.24%)
  • Silver

    -0.25 (-0.99%)

    -0.0063 (-0.52%)
  • 10-Yr Bond

    +0.0140 (+0.90%)

    -0.0065 (-0.47%)

    +0.2090 (+0.19%)

    -1,314.40 (-2.66%)
  • CMC Crypto 200

    +18.53 (+1.96%)
  • FTSE 100

    +16.53 (+0.25%)
  • Nikkei 225

    -65.78 (-0.23%)

Rosen, A Global and Leading Law Firm, Announces an Investigation of Securities Claims Against Homology Medicines, Inc.; Encourages Investors with Losses in Excess of $100K to Contact Firm - FIXX

  • Oops!
    Something went wrong.
    Please try again later.
Newsfile Corp.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

New York, New York--(Newsfile Corp. - October 15, 2020) - Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Homology Medicines, Inc. (NASDAQ: FIXX) resulting from allegations that Homology may have issued materially misleading business information to the investing public.

On July 21, 2020, Mariner Research published a report questioning statements by Homology and its officers about the efficacy of HMI-102, the Company's lead product candidate for treatment of phenylketonuria. The Mariner report focused on Homology's HMI-102 dose escalation pheNIX trial, concluding that the Company concealed data showing HMI-102's lack of efficacy and indicating that the program was unlikely to proceed to commercialization. Among other evidence, the Mariner report cited an email from Homology's Chief Communications Officer appearing to indicate the Company's awareness that a HMI-102 high dose patient had adverted to the adverse efficacy issue in a social media post during April 2020.

On this news, Homology's stock price fell $1.71 per share, or 10%, over the following three trading days, closing at $14.77 per share on July 24, 2020.

Rosen Law Firm is preparing a securities lawsuit on behalf of Homology shareholders. If you purchased securities of Homology please visit the firm's website at http://www.rosenlegal.com/cases-register-1968.html to join the securities action. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or cases@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm's attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.


Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/66037